New drug will come in the market for the treatment of type 2 diabetes, Mankind Pharma seeks approval from CDSCO

Mankind Pharma is the fourth largest pharmaceutical company in India. The company has attempted to develop a new class of anti-diabetic molecules. After the approval of CDSCO, this drug will be launched first in its class. It is expected that it will bring great relief to diabetics and prove to be highly effective in reducing blood sugar levels.

New Delhi. The Drugs Regulatory Authority of India, Central Drugs Standard Control Organization (CDSCO) submitted its first Investigational New Drug application for Mankind Pharma Company to get approval from the Drug Regulatory Authority of India. MKP10241 is the first patented Novel Anti Diabetic Molecule in its class. Mankind Pharma is the fourth largest pharmaceutical company in India according to IQVIA.

The company has continuously worked hard to develop this new class of Anti-Diabetic Molecules. It has been designed and developed at Mankind Research Center. MKP10241 is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is found in high concentrations in pancreatic beta cells and intestinal cells.

After the approval of CDSCO, this drug will be launched first in its class. The company sincerely hopes that it will provide great relief to patients suffering from diabetes and will prove to be highly effective in reducing blood sugar levels.

What makes MKP10241 special is its mechanism of action. GPR119 increases the movement of intracellular secondary messengers such as cAMP within cells and also promotes postprandial insulin and incretin secretion (GLP-1) while maintaining glucose dependence.

This mechanism of dual function by GPR119 in maintaining the balance of glucose-dependent insulin secretion differs from currently available therapeutic options for type 2 diabetes. Thus it becomes a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.

These small molecules with GPR119 agonist properties will help the Indian pharma industry to provide new therapeutic options in the antidiabetic segment for the treatment of type 2 diabetes.

It was tested in several preclinical models of type 2 diabetes to understand the new drug’s mode of action and its efficacy. It has shown effective results in lowering blood sugar levels and glycated hemoglobin.

MKP10241 increases plasma insulin as well as plasma GLP-1 levels and ultimately lowers plasma glucose in preclinical models by exerting a dual action associated with GPR119. MKP 10241 has already been patented worldwide by 2037.

On this historic occasion, Mankind Pharma Executive Chairman R. C. Juneja said that ‘Our team of scientists has worked tirelessly and with full passion to develop this drug to benefit the people. It will be affordable for the patients.

Mankind Pharma is committed to expand its portfolio of products in the Indian market across all major therapeutic areas for the benefit of patients, doctors and the entire healthcare system.

The company believes that if we can deliver the right medicine to the right patient through the right route at the right time, it will ultimately effectively strengthen and improve the health care system.

Significantly, the company has registered a strong presence in the Pharmaceutical, Veterinary, OTC and FMCG segments.